Company: BDRX
Filing Date: 2025-09-26
Form Type: F-3
Source: 0001214659-25-014255
Chunk: 102

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-26
Form: F-3
Chunk 102
---
 applicable, the exercise price for our Depositary Shares and the number of Depositary Shares to be 
 received upon exercise;                                                                               |

| · | the date on which the right to exercise the warrants will begin and the date on which that right will                                     
 expire or, if you may not continuously exercise the warrants throughout that period, the specific date or dates on which you may exercise 
 the warrants;                                                                                                                             |

| · | whether the warrants will be issued in fully registered form or bearer form, in definitive or global form                                
 or in any combination of these forms, although, in any case, the form of a warrant included in a unit will correspond to the form of the 
 unit and of any security included in that unit;                                                                                          |

| · | any applicable material United States federal income tax consequences and any applicable material United 
 Kingdom tax consequences;                                                                                |

| · | the identity of the warrant agent for the warrants, if any, and of any other depositaries, execution or 
 paying agents, transfer agents, registrars or other agents;                                             |

| · | the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants 
 on any securities exchange;                                                                               |

| · | if applicable, the date from and after which the warrants and the Depositary Shares and/or debt securities 
 will be separately transferable;                                                                           |

| · | if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time; |

| · | information with respect to book-entry procedures, if any; |

| · | the anti-dilution provisions of the warrants, if any; |

| · | any redemption or call provisions, if any; |

| · | whether the warrants may be sold separately or with other securities as parts of units; and |

| · | any additional terms of the warrants, including terms, procedures and limitations relating to the exchange 
 and exercise of the warrants.                                                                              |

Transfer Agent and Registrar

The transfer agent and registrar
for any warrants will be set forth in the applicable prospectus supplement.

| 57 |

<div align='center'>DESCRIPTION OF RIGHTS</div>

General

We may issue rights to our
shareholders to purchase our Ordinary Shares, including Ordinary Shares represented by Depositary Shares or the other securities described
in this prospectus. We may offer rights separately or together with one or more additional rights, debt securities, Ordinary Shares, including
Ordinary Shares, represented by Depositary Shares, or warrants, or any combination of